Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
Medtronic beats Q2 FY26 earnings and revenue estimates, driven by 71% growth in its Cardiac Ablation Solutions business. The company also raised its full-year guidance.
Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.
It’s a big week for earnings this week with Nvidia and some key retail names taking center stage. This week we have Nvidia, Home Depot, Walmart, Target, Lowes, Palo Alto Networks, Medtronic and Pdd Holdings all reporting.
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the sector's
NEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the third quarter ended September 30, 2025, and provided a business update highlighting recent financial and regulatory milestones.
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
Volta Medical has officially launched its groundbreaking AI-powered AF-Xplorer II system in the U.S. on November 5, 2025, marking a pivotal moment in the treatment of complex atrial fibrillation (AF). This next-generation artificial intelligence solution is designed to act as a digital companion for electrophysiologists, providing real-time assessment of complex AF and atrial tachycardia during [...]
Medtronic (MDT) presents a strong value investment case with attractive valuation multiples, solid profitability, and a healthy financial position, trading below its inherent worth.
